Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,290.00
(
0.65%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.42
(
-0.23%
)
Bitcoin
74,278.33
(
0.45%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 101525

Wednesday, 09/28/2011 5:12:46 AM

Wednesday, September 28, 2011 5:12:46 AM

Post# of 257253
Astellas terminates development of darexaban (YM150):

http://www.reuters.com/article/2011/09/28/astellas-idUSL3E7KS17D20110928

The decision is not surprising insofar as darexaban was a day late and a dollar short relative to the competition (Xarelto, Eliquis, Pradaxa), as discussed in the prologue of #msg-66651733. Astellas previously submitted an application for marketing approval in Japan (#msg-55022218), but then quietly withdrew the application.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up